Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Work In Process (2022 - 2025)

Axsome Therapeutics (AXSM) has disclosed Work In Process for 4 consecutive years, with $17.8 million as the latest value for Q4 2025.

  • Quarterly Work In Process rose 130.95% to $17.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $17.8 million through Dec 2025, up 130.95% year-over-year, with the annual reading at $17.8 million for FY2025, 130.95% up from the prior year.
  • Work In Process hit $17.8 million in Q4 2025 for Axsome Therapeutics, up from $12.9 million in the prior quarter.
  • In the past five years, Work In Process ranged from a high of $17.8 million in Q4 2025 to a low of $6.8 million in Q1 2025.
  • Historically, Work In Process has averaged $10.6 million across 4 years, with a median of $10.4 million in 2023.
  • Biggest YoY gain for Work In Process was 130.95% in 2025; the steepest drop was 37.64% in 2025.
  • Year by year, Work In Process stood at $14.0 million in 2022, then fell by 26.34% to $10.3 million in 2023, then fell by 24.92% to $7.7 million in 2024, then soared by 130.95% to $17.8 million in 2025.
  • Business Quant data shows Work In Process for AXSM at $17.8 million in Q4 2025, $12.9 million in Q3 2025, and $7.5 million in Q2 2025.